Multiple Genetic Abnormalities in Myeloma: Implications for Treatment

Submitted by Dr. Brian GM Durie on Thu, 01/16/2014 - 00:00
A recent article in the medical journal Cancer Cell documents the widespread chromosomal abnormalities present in myeloma cells. The sobering data from this study, the largest of its kind, also demonstrate why the promise of individual therapies targeted against individual genes is fading--and why the Black Swan Research Initiative approach offers a smarter plan of attack against myeloma.
 

Black Swan Research Initiative Hits the Ground Running in 2014

Submitted by Dr. Brian GM Durie on Thu, 01/09/2014 - 00:00
The International Myeloma Foundation (IMF) Black Swan Research Initiative (BSRI)  is moving into high gear in the new year.
 

Can Studies of a Single Cell Lead to the Cure for Myeloma?

Submitted by Dr. Brian GM Durie on Thu, 12/19/2013 - 00:00
In the current issue of the journal Science there is a special section called "Single-Cell Biology" (cells go solo). It is now technically feasible to study individual cells in great detail at the molecular, metabolic and functional levels. What is being discovered is that a reading of the "average" from 100, 1,000 or a million cells as has previously been done disguises the great diversity at the individual cell level. 
 

Research at ASH 2013 Points the Way Forward for Myeloma Patients

Submitted by Dr. Brian GM Durie on Thu, 12/12/2013 - 00:00
This year's annual meeting of the American Hematological Society (ASH) was truly exhausting, but especially exciting. So many abstracts, so little time!  One had to be a magician to cover major sessions running in parallel. Add to that the cold weather in New Orleans, travel delays, a vast, maze-like, conference center, and you end up with multiple 18-hour days.
 

ASH 2013 Preview, Part 2: From New Drugs to the Biology of Myeloma

Submitted by Dr. Brian GM Durie on Tue, 11/19/2013 - 00:00
Last week, in Part I of my overview of abstracts released by the American Society of Hematology (ASH) in advance of the group's annual meeting in New Orleans, I focused on combinations using the approved novel agents.

Pages

more